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“Of Vital Importance”: The New York State Task Force
on Life and the Law’s Report and Recommendations for
Research with Human Subjects Who Lack Consent Capacity
By Valerie Gutmann Koch and Susie A. Han
American history has been rife with human subjects
research (HSR) scandals—particularly those that involve
“vulnerable” populations—including several in New
York State, such as those that occurred at the Willowbrook State School and the Jewish Chronic Disease Hospital.1 In response, state and federal laws and regulations
were enacted to ensure voluntary informed consent for
participants and institutional review board (IRB) oversight of HSR. However, these laws and regulations do not
provide any special oversight mechanisms or protections
to ensure the ethical and safe inclusion of cognitively
impaired adults in research.
Although research involving adults lacking consent
capacity is permitted in New York State, until recently it
was limited because of uncertainty about who could provide surrogate consent to participation. In 2010, the Family Health Care Decisions Act changed the legal landscape
by permitting surrogate consent to health care and potentially opened up the field of research requiring surrogate
consent. However, there remain few—if any—rules and
little guidance at both the federal and state level to ensure
consistently ethical conduct of research involving adults
lacking consent capacity. While some institutions and
investigators are conducting researching with this population without oversight or guidance, others are taking an
extremely conservative approach and are excluding these
individuals from research, citing concerns about vulnerability and exploitation. Without safeguards that are both
adequate and robust but not overly burdensome, this
will remain a challenge to the conduct of ethical research.
Thus, IRBs, investigators, and research institutions have
appealed to the New York State Task Force on Life and
the Law (the Task Force)2 for guidance on how to conduct
research involving this vulnerable population.
Human subjects research plays an essential role
in advancing biomedical and behavioral science and
strengthening our ability to prevent and treat human diseases and medical conditions. The optimal condition for
research involving human subjects is for the participant
to provide first-person informed consent. To learn about
and seek cures for the broad range of diseases that impair
cognition, however, research requires the participation
of individuals who cannot themselves provide informed
consent. Laws that exclude individuals who lack consent capacity actually disadvantage this population by
preventing scientific advances for conditions that cause
decisional incapacity. Although concerns about how to
conduct research involving individuals unable to give
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first-person informed consent are valid and important,
justice requires the creation of guidance and procedures
that will allow these individuals to benefit from scientific
advances while ensuring that their interests are protected.
To address this significant inconsistency in the oversight and conduct of research, the Task Force drafted a
set of legal and ethical guidance regarding the conduct
of research in New York State involving adults who lack
consent capacity. This article addresses the development
and key content of the guidance, which may serve as a
model for research in other states and at the federal level.
An underlying goal of the work is to ensure that research
protocols are available to all individuals, including this
population, so that they may also experience the benefits of research and share its risks and burdens as their
non-cognitively impaired peers, while also ensuring the
appropriate level of protections. Thus, the report provides
guidance and best practices that will assist institutions,
researchers, IRBs, and surrogate decision-makers in the
ethical conduct and responsibilities of research involving
the cognitively impaired. Without such guidance, either
research will occur without appropriate protections and
safeguards, or important research may not occur.

Methods
At the request of various stakeholders, the Task Force
analyzed the legal and ethical implications of research
involving adults lacking consent capacity. The Task Force
began this endeavor in December 2007 by disseminating
a survey to approximately 300 New York IRB chairs and
members that requested information about their institutions’ practices, if any, for conducting research involving
the cognitively impaired, and their views on the regulatory landscape. More than 100 responses provided a
detailed and useful qualitative account of research practices in New York, and indicated a need for guidelines to
ensure consistently ethical research practices.
Since 2007, the Task Force has devoted itself to examining the issues associated with research involving cognitively impaired adults. It reviewed medical and policy
literature on human subjects research, informed consent,
surrogate consent, capacity assessment, risk-benefit
analysis, research protections, adverse events, and related
topics. It conducted extensive legal research of federal and
state regulatory standards, including New York’s, and
case studies pertaining to human subjects research involving the cognitively impaired. It reached out and relied on
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testimony from several experts from research institutions,
governmental entities, and patient advocacy organizations. The Task Force analyzed previously released
reports, recommendations, and draft regulations on human subjects research by the Department of Health and
the public comments to these efforts,3 and stakeholders
and other interested parties provided additional perspectives and input on this project. It also took into account
the controversial advisory opinion in the case T.D. v. N.Y.
State Office of Mental Health,4 in which the court addressed
the need for special protections where research includes
individuals who lack consent capacity when surrogate
consent is used.
In developing these guidelines, the Task Force considered and declined to recommend legislation governing research involving individuals who lack consent
capacity. It concluded that because existing law permits
research involving this population,5 no statutory change
is needed. The Task Force therefore identified approaches
that comply with current federal and state law, including
the Common Rule and New York Public Health Law 24A,6 to ensure ethical practices in research involving this
vulnerable population.

Recommendations
In order to promote a consistently ethical approach
by institutions to the protection of this vulnerable population in New York State, the Task Force made a number
of important and—in some cases—unique recommendations regarding including individuals who lack consent
capacity in human subjects research.7 This guidance is
necessary in order to ensure that this population is able
to participate in research (as the law anticipates) with
adequate and appropriate safeguards in place.
A.

Participant Selection

The Task Force recommends that researchers and
IRBs must ensure that there is justification for involving
participants who lack consent capacity in research protocols, and in general, that the least burdened populations
should be used as research participants wherever possible. Availability, compromised position, or ease of recruitment are insufficient reasons to justify the inclusion
of a specific vulnerable group in research. The inclusion
of such individuals may be appropriate in research that
offers potential benefits to participants when standard
clinical approaches are ineffective, unproven, or unsatisfactory, or when research is reviewing a new, improved
standard of care that may be more effective for conditions
that uniquely affect that specific population. Furthermore, IRBs should pay particular attention to the rationale behind enrolling vulnerable patients for research
protocols that do not explicitly study medical conditions
that impair consent capacity.
In addition, the Task Force recommends that the institutional setting for research must be scrutinized when
28

choosing the least burdened population. If researchers
propose to utilize nursing home residents or institutionalized patients, they should demonstrate why that venue is
necessary,8 because research involving these groups may
be seen as increasing the risks and potential harms for an
already burdened population.9
Where possible, particularly for high risk or nodirect-benefit research, IRBs should require research
protocols to include evidence of safety and efficacy data
from studies conducted in a non-impaired group prior to
inclusion of cognitively impaired individuals. However,
in certain circumstances, the potential benefit is unique to
the cognitively impaired population, or the characteristics
of the non-impaired participants may differ so greatly
from the impaired population that such evidence may not
be available.
B.

Benefits and Risks

The Task Force recommends that, in reviewing proposed research protocols, IRBs consider whether same
or similar benefits are available outside the context of
research, the intent of the researcher and purpose of the
study, the likelihood that all participants will receive the
benefit, and the extent or amount of the potential direct
benefit.
One of the core functions of an IRB is to review and
approve studies that present a reasonable balance of
potential benefits to risks. Research protocols can be classified as either prospect-of-direct-benefit or no-direct-benefit
studies, based on the likelihood that the research will
result in direct benefits that improve the health or wellbeing of a participant by procedures or interventions that
are outside of standard health care treatment. Prospectof-direct-benefit research has a reasonable probability of
providing the proposed benefit. No-direct-benefit studies
have a negligible or nonexistent probability of offering a
benefit to participants.
One of the most complex ethical issues in conducting
research involving these individuals is the degree of risk
to which researchers may ethically expose this population. While upper limits on the level of acceptable risk
may be necessary for some HSR studies, bright-line cutoffs are only appropriate in limited circumstances. The
Task Force recommends that research should only be approved for individuals who have first explored all available treatment and research options and failed to receive
any therapeutic benefit, and for those without any other
known treatment or research options available.
In 1977, the National Commission issued a report
on research involving children, suggesting a tripartite
scheme for classifying research risks.10 These three classifications are: (1) minimal risk; (2) minor increase over
minimal risk; and (3) more than a minor increase over
minimal risk. This scheme was incorporated into the
federal regulations for research with children11 and has
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been used in numerous expert commission reports and
state regulations delineating research risk in all human
subjects research.12 Although the tripartite risk scheme
presents difficulties in application, it remains the most
recognized and most used method to classify risks levels.
The Task Force concluded that these three major risk
levels are appropriate for IRBs and researchers to use for
research involving individuals who lack consent capacity.
The Task Force recommends that for all human subjects research, the risk level should be minimized wherever possible to achieve the research objective. Although
risk may never be eliminated completely in some studies,
the Task Force recommends that procedures should be
in place to assure an appropriate level of care for participants, including personalized attention to ensure safety
and the use of required medical and therapeutic procedures where appropriate.
When research involves vulnerable individuals, the
Task Force recommends that it is appropriate for IRBs
to establish a lower ceiling for allowable risk or require
a more favorable risk-benefit ratio for a protocol to be
approved than they would for similar research involving
non-vulnerable participants. However, for research that
may offer a prospect of direct benefit, an IRB may allow a
higher ceiling for allowable risk and allow a less favorable risk-benefit ratio for research.
For research that is categorized as offering no prospect of direct benefit, it may nevertheless be unclear
whether the study has more than a negligible prospect of
direct benefit or, if more than negligible, how much more;
clarity (or its absence) often depends on the current state
of available scientific knowledge. In such cases, where
research offers no clear prospect of direct benefit, IRBs
should determine whether the research is of “vital importance.” For research to be considered of vital importance,
there must be clear and significant scientific evidence
that the use of such a procedure or intervention presents
a reasonable opportunity to further the understanding
of the etiology, prevention, diagnosis, pathophysiology,
or alleviation or treatment of a condition or disorder.13
The IRB should carefully review the hypotheses of the
study and antecedent evidence, such as data from animal
studies, analogous research,14 or toxicity trial results, to
evaluate whether the research is vitally important to the
research population and will contribute knowledge about
the disorder or condition. Furthermore, the IRB should
also examine the researchers’ therapeutic intent15 and the
purpose of the research study to determine whether the
research is of vital importance and should be approved.
The Task Force recommends that it is acceptable for
IRBs to require additional safeguards (such as requiring
or recommending informed consent monitors (ICMs) and
medically responsible clinicians (MRCs)) to ensure the
safety and well-being of vulnerable participants. Both the
degree of scrutiny by an IRB and the determination of
the number and type of additional protections required
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should be unique to each study, and should be calibrated
according to the risk level and the likelihood and significance of any direct benefit.
The Task Force recommends the following approach
to oversee risk-benefit ratios for research involving individuals lacking consent capacity:
For research with minimal risk and a prospect of direct
benefit to the participant, IRBs may approve such studies
if the risks are reasonable in relation to the prospective
benefits.
For research with minimal risk and no prospect of direct
benefit to the participant, IRBs may approve such studies if the research is important to advance the scientific
knowledge of a medical condition that affects the research
population, and if the risks are reasonable in relation to
such importance. Ethical issues related to research with
minimal risk, with or without a prospect of direct benefit, are often manageable. IRBs, researchers, surrogate
decision-makers, and potential participants should expect
to resolve them without severely impeding research
or unreasonably risking the participants’ welfare, particularly when the beneficial prospect is more certain,
or the benefit is expected to be more frequent or more
significant.
For research with a minor increase over minimal risk
and a prospect of direct benefit to the participant, IRBs may
approve such studies only if the risks are reasonable in relation to the prospective benefits, if the potential benefits
are similar to those available in the standard clinical or
treatment setting, and if the risk-benefit ratio is favorable
to participants. Such ratios are more favorable when the
beneficial prospect is more certain or the benefit is expected to be more frequent or more significant. IRBs may
recommend the use of ICMs, MRCs, or other additional
safeguards.
For research with a minor increase over minimal risk
and no prospect of direct benefit to the participant, IRBs may
approve such studies only if the research is vitally important to further the understanding of the etiology, prevention, diagnosis, pathophysiology, or alleviation or treatment of a condition or disorder that affects the research
population, and if the risks are reasonable in relation to
the research’s “vital importance.”16 Furthermore, IRBs
may approve such studies only if they require mandatory
rigorous procedures and oversight for enrollment and
monitoring of participants through the use of safeguards,
including an ICM and an MRC.
For research with a more than a minor increase over
minimal risk and a prospect of direct benefit to the participant, IRBs may approve such studies only if the risks
are reasonable in relation to the prospective benefits, if
the potential benefits are similar to those available in the
standard clinical or treatment setting, and if the riskbenefit ratio is favorable to participants. Such ratios are
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less favorable when the risk is substantially more than a
minor increase over minimal risk. Such ratios are more
favorable when the prospect of direct benefit is more
certain, or the benefit is expected to be more frequent or
more significant. IRBs should require the use of ICMs and
MRCs.
For research with more than a minor increase over
minimal risk and no prospect of direct benefit to the participant, IRBs may approve such studies in only two circumscribed circumstances: where the potential participants
have a research advance directive or in special situations
with notification to the Department of Health and use of
a special review panel. These two scenarios are addressed
in the following subsections.
1.

Use of Research Advance Directives (RADs)

The Task Force recommends that IRBs may approve
studies in this risk-benefit category if all potential participants have, when they still had capacity, executed
legally binding documents such as Research Advance
Directives (RADs), which provide an individual’s instructions for future research participation should s/he lose
consent capacity, that explicitly state that they are willing
to participate in this category of research. However, even
if all participants have signed RADs, IRBs may approve
such studies only if the research is of vital importance to
the understanding of the etiology, prevention, diagnosis,
pathophysiology, or alleviation or treatment of a condition or disorder that affects the research population and/
or those similarly situated. The IRB must determine that
such risks are reasonable in relation to the research’s vital
importance. Such risks are less likely to be reasonable if
they are substantially, rather than marginally, more than
a minor increase over minimal risk. Furthermore, IRBs
may approve such studies only if they require mandatory
rigorous procedures and oversight for enrollment and
monitoring of participants through the use of safeguards,
including an ICM and an MRC.
2.

Notification to the Department of Health and
Use of a Special Review Panel

Because so few people have RADs, the Task Force
concluded that an alternative mechanism for innovative
research to be approved in very limited circumstances
may be necessary, and thus there are limited circumstances where a research protocol may be considered for
approval even where potential participants do not have
RADs. The Task Force therefore recommends a second
mechanism for IRBs to approve studies with more than
a minor increase over minimal risk and no prospect of
direct benefit. This alternative approval process consists
of several steps: (1) IRB review, (2) Department of Health
notification by the IRB and possible referral by the Department to a special review panel, and (3) IRB decision
to approve or reject the research protocol.
For a protocol to be considered under this alternative
process, the IRB must first examine whether the research
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is of vital importance to the understanding of the etiology, prevention, diagnosis, pathophysiology, or alleviation or treatment of a condition or disorder that affects
the research population, and if the risks are reasonable
in relation to the research’s vital importance. Such risks
are less likely to be reasonable if they are substantially,
rather than marginally, more than a minor increase over
minimal risk. In addition, as noted above, although this
type of research protocol must be labeled as offering no
prospect of direct benefit, for some research participants,
a remote possibility exists that they (or others similarly
situated) may benefit from the research or from the
knowledge gained.17 In such cases, the IRB must consider whether this remote possibility of benefit exists for
potential participants, and weigh it against the potential
risks of the protocol. Furthermore, the IRB should ensure
that the study requires rigorous procedures and oversight
for enrollment and monitoring of participants through the
use of safeguards, including an ICM and MRC.
If the IRB concludes that the research is of vital
importance to either current research participants and/
or those similarly situated, that the risks are reasonable
in relation to such vital importance, and appropriate
safeguards are in place, such as the ICM and MRC addressed above, the IRB should notify the Department of
Health. At the discretion of the Department of Health,
the Department may: (1) reject the study (and thus the
research could not be approved by the IRB), (2) approve
the study (whereby the research could be approved by
the IRB), or (3) convene a special review panel of experts18
who will examine the study and issue recommendations
to the IRB on whether the study should be approved. If
the Department of Health decides that a special review
panel must examine the protocol, after the special panel
has made its recommendations, the Department should
refer the protocol back to the IRB for review and the IRB
will make the final determination based on the panel’s
recommendations.
The special review panel should be comprised
of experts knowledgeable about the conditions(s) or
population(s) addressed by the research, to ensure that
the reviewers are well-informed about the research topic
and can provide meaningful commentary to aid in the
IRB’s decision-making.19 While the Task Force acknowledges that the use of a special review panel may delay
approval or the commencement of the study, this procedural process is important to safeguard participants.
Furthermore, because only a small proportion of stateregulated research would fall into this risk-benefit category, the number of protocols that would be referred to
a special review panel would likely be small. Thus, use of
these panels would acknowledge the need for innovative
research using the existing regulatory framework (i.e.,
respecting the IRB purpose and structure) and would also
ensure that unethical research would not be conducted
(supporting the IRB’s opinion whether the protocol may
be approved).
NYSBA Health Law Journal | Spring 2014 | Vol. 19 | No. 1

Where a protocol has been referred to a special
review panel by the Department of Health, the panelists
should be required to provide a written report that will
be publicly available, which will include a summary of
the panel’s reasoning, analysis, and recommendation
to the IRB. The recommendations will advise the IRB to
either reject or approve the study, and will include any
modifications to the protocol. In the final step of this process, the IRB would then review the recommendations
and decide to approve or reject the study.
The panelists should also forward their recommendations to the Department of Health for record keeping.
The Department of Health should keep the individual
panel members’ recommendations on file and make them
available to the public upon request, which would provide a historical record of the types of research studies
considered by these panels. This information may help
guide researchers as they design future studies, assist
IRBs with their review and oversight process of this type
of risk-benefit research, and promote transparency for the
general public to maintain confidence in the oversight
process of this category of unique research.
C.

Consent and Capacity Assessments

Informed consent is a fundamental tenet of ethically
and legally acceptable human subjects research because it
helps protect individuals from involuntary participation
and exposure to risk. The Task Force recommends that,
where possible, informed consent should be obtained in
a dynamic process, as part of a continued dialogue between the potential participant and the person presenting
the research protocol. The information should be presented using methods that are best suited to the capacity
level of the target population. Asking detailed questions
and having a discussion about the study with a knowledgeable person will help guide a potential participant in
making a careful decision about whether research enrollment is appropriate (i.e., first-person decision-making).
The focus of the informed consent process should be on
this conversation and comprehension, rather than on the
technicalities of the consent form. The Task Force recommends that informed consent be obtained, with the use of
a neutral discloser, before enrollment in a research study,
but should also be re-obtained when circumstances significantly change the potential benefits or risks or harms,
or when new scientific information becomes available.
Cognitively impaired adults who do not have the capacity to provide first-person informed consent may nevertheless retain sufficient capacity to understand some of
the more basic concepts involved in a research study and
provide assent—affirmative agreement—to participate in
the proposed research. Therefore, to preserve the autonomy of potential participants who are capable of assent,
the Task Force recommends that researchers must seek
assent from such participants in addition to informed
consent from a surrogate.20
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The Task Force recommends that where a potential
participant is unable to provide or express assent, researchers must look for signs of dissent—the objection or
resistance to participate in the study – both at the initiation of the study as well as once the participant is enrolled. Researchers should recognize that for this population, dissent may not be obvious. Furthermore, if signs of
dissent are present, the researcher may not enroll or allow
continued participation of the individual in the study.
Any participant who enrolls in a research protocol
has the freedom to withdraw from the study without
prejudice at any time, and this decision to withdraw
should be respected. However, participants who have
impaired consent capacity may be unable to express their
preference to withdraw from the research. The Task Force
recommends that researchers develop formal procedures
to ensure that appropriate withdrawal mechanisms are
available to the research population, that any withdrawal
is accomplished with the least risk to the participant, and
that any withdrawal, including the reason for it, is properly reported to the IRB.
Consent capacity may be impaired due to medical
conditions or illnesses, chronic diseases, medication, or
developmental cognitive impairment.21 Moreover, lack
of capacity may be temporary or permanent, depending
on the condition. Consent capacity is best understood
as occurring along a continuum—it is not simply either
present or absent. Although an individual may exhibit a
degree of cognitive impairment, it should not be assumed
that the person does not retain sufficient capacity to
consent or decline to participate in all research studies.22
Consent capacity has a complicated relationship to clinical diagnosis and is likely to fluctuate over time and may
be task-specific. Determining whether a participant has
sufficient consent capacity depends not only on the individual, but on the complexity of the research protocol and
the risks and benefits associated with that protocol. Thus,
the threshold that distinguishes individuals who meet
the consent capacity standard varies between research
protocols.
Current practices for screening and evaluating consent capacity vary in type23 and quality.24 Selection of the
best method for assessing consent capacity depends in
part on the use researchers will make of the outcome. In
cases where researchers seek to exclude all participants
who lack consent capacity, briefer screening tools may
suffice. For protocols in which researchers intend to enroll
impaired individuals who require either remediation or
other consent enhancement techniques to meet criteria
for consent capacity, a more detailed evaluation tool may
be most useful. In addition, proper use of the capacity
evaluation tool may also be contingent on the inclusion
or exclusion criteria of the research protocol. The Task
Force recommends that researchers seeking approval
of a study involving the cognitively impaired should
provide the IRB with a description of the procedures and
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methods to be used for the initial capacity assessment,
as well as how capacity will be monitored through the
course of the study (if appropriate), and include information about who will conduct the assessment and his/her
qualifications.
D.

Legally Authorized Representatives

When researchers are unable to obtain first-person
informed consent from a potential participant, researchers may—depending on the nature of the study and the
risk-benefit ratio—be permitted to enroll an individual
using surrogate informed consent or according to a
potential participant’s RAD. However, neither the federal
nor state governments have directly addressed who
should act as a research legally authorized representative
(LAR) for the cognitively impaired.25 If the legislature or
Department of Health promulgates rules in the future
regarding who may consent, different considerations and
standards of decision-making should apply to research
than to treatment.26
The Task Force recognizes that, ideally, an individual
should select an LAR before s/he no longer has consent
capacity, using a legally binding document, such as a
health care proxy or RAD. The Task Force prefers such
appointments because it assumes that the appointed
LAR has a close relationship with the individual and that
a discussion regarding research preferences has taken
place. In some cases, a cognitively impaired adult may
retain sufficient capacity to choose a research proxy—a
research agent—to make research decisions on his/her
behalf, but lack capacity to consent to research participation him/herself.27 Strict procedural mechanisms and
safeguards, similar to those used in a health care proxy
designation appointed while the individual has consent
capacity, should be in place to ensure that an individual’s
appointment of a research agent using a legally binding document is an unbiased and free choice.28 The Task
Force also recommends the placement of restrictions on
who may serve as an LAR to ensure that participants are
adequately protected.29
Where an RAD has not been previously executed, it
may be permissible, in some cases, for individuals lacking consent capacity to be enrolled in a research protocol
with the consent of an LAR. Federal law clearly contemplates allowing surrogates to consent to research involving adults who lack consent capacity.30 An LAR is defined
under the Common Rule as “an individual or judicial
body authorized under applicable law to consent on behalf of a prospective subject to the subject’s participation
in the procedure(s) involved in the research….”31 However, federal law defers to the states to establish who may
serve as an LAR, looking to their formulations of LAR
to determine who may consent to research conducted in
that state. Because New York’s laws for human subjects
research do not provide a research-related LAR hierarchy,
the 2010 passage of the Family Health Care Decisions
Act (FHCDA) changed the legal landscape by permitting
32

surrogate consent to health care.32 The surrogate hierarchy contained in the FHCDA thus opened up the field of
research requiring surrogate consent in New York State.
While hierarchies are practical for determining who
may serve as an LAR, not all LARs are ethical equivalents, particularly when considering research enrollment
decisions. Because LARs listed in a hierarchy often will
have varying degrees of kinship, intimacy, and understanding of the wishes of the impaired individual regarding research participation, it is important to consider the
relationship between the LAR and the potential participant with respect to the type of research and risk level
involved. An LAR who has a close relationship with the
impaired individual would be the most familiar with
whether s/he would choose to participate in research and
under what circumstances. Thus, the Task Force recommends that IRBs and researchers consider limiting the
classes of LAR(s) who are authorized to provide surrogate
consent to research. The riskier the research protocol and
more remote the prospect of benefit, the closer (by kinship
or intimacy level) the LAR should be to an individual
to be imbued with authority to consent to the impaired
individual’s participation in the study.33
When determining whether an individual should
participate in research, an LAR should use instructions
from an RAD or similar type of advance directive, if such
instructions exist; or the participant’s prior expressed
wishes and preferences about research, if known. If there
are no prior expressed wishes, the LAR should use either
the best interest standard or substituted judgment.
Finally, to prevent undue inducement to consent to
research, LARs may never be the true beneficiary of any
financial compensation offered.
E.

Notice to Participant and Opportunity for Review

The Task Force emphasized the importance of procedures for providing notice to the potential research
participant and, if necessary, the LAR, regarding the
capacity assessment and opportunities for objection and
review. Researchers should provide notice to the potential
participant and/or LAR that an assessment will be conducted and the consequences (if any) of a determination
of incapacity.
As part of a research protocol, the Task Force recommends that potential participants and/or LARs should
be notified of a planned capacity assessment, as well as
the results of the assessment and any consequences of a
determination of incapacity. Providing notice promotes
transparency by alleviating any concerns that an individual might be involved in research without the knowledge
of the participant or LAR. It also demonstrates respect for
the prospective participant by presenting an opportunity
for the individual or his/her LAR to object to either the
capacity assessment or the results of the evaluation. When
capacity assessments are contested, the most ethical
NYSBA Health Law Journal | Spring 2014 | Vol. 19 | No. 1

alternative may be to decline to enroll the individual in
the research protocol. However, in some cases, alternatives short of non-enrollment could appropriately deal
with any objection, such as a second capacity assessment.
Readily available review procedures allow individuals an
opportunity to request further information or a second
opinion where they or their LARs see fit. Furthermore,
steps should be taken during the notification process to
ensure that the results of the capacity assessment remain confidential and that the privacy of the individual
is respected. Finally, the Task Force recommends that
researchers inform patients of whether the results of the
assessment will be entered into an individual’s medical
record.
F.

Additional Safeguards for Research Participants
Lacking Consent Capacity

Additional protections might sometimes be necessary to safeguard the rights of participants who lack
consent capacity, particularly when a study involves a
minor increase over minimal risk or more than a minor
increase over minimal risk, and when there is no prospect of direct benefit to the participant. The amount and
scope of additional safeguards that the Task Force recommends for research with this population depends on the
level of risk and the likelihood of direct benefit that the
research protocol offers to the research participant. Such
protective measures may include, but are not limited to:
(1) independent consent monitors; (2) medically responsible clinicians; (3) state multiple project assurances; and
(4) additional reporting requirements.
1.

Independent Consent Monitors (ICMs)

By commonly accepted definitions, an ICM is an
individual not affiliated with the study or research
institution, who is designated by an IRB to monitor the
informed consent process34—for example, when LAR
consent is required. In some cases, this safeguard may
provide additional protection for potential participants,
because an ICM’s duties include ensuring that as a witness to the consent process, verification of valid consent
is properly obtained.35 An ICM provides confirmation
that adults lacking consent capacity are enrolled in
research protocols only when appropriate informed consent procedures are followed. In addition, an ICM may
also confirm that LARs understand the goals and risks of
the research by observing the informed consent process.36
Furthermore, an ICM may provide independent assurance that an adult lacking consent capacity is enrolled
in research only when there is sufficient evidence that
such participation is consistent with the person’s preferences and/or interests. For some research protocols, an
ICM may have a more active role as an advocate for the
potential participant and LAR during the recruitment
process and possibly for the entire research study.37 The
ICM may serve as a resource to help potential participants and LARs understand the potential risks and
NYSBA Health Law Journal | Spring 2014 | Vol. 19 | No. 1

benefits and decide if enrollment in a research protocol
would be appropriate.38
The Task Force recommends that the role and responsibilities of an ICM may vary, from monitoring the
informed consent process to advocating on behalf of potential and current research participants, and the degree
of involvement of the ICM would be determined by an
IRB. After reviewing the research protocol and the riskbenefit level involved, an IRB may determine the scope of
responsibilities of an ICM.
2.

Medically Responsible Clinicians (MRCs)

Depending on the research study and risk level
involved, use of an MRC for each participant may be a
necessary safeguard to protect cognitively impaired individuals. An MRC is a licensed medical doctor skilled and
experienced in working with the research population and
is independent from the study. Ideally, this person should
be the physician already attending to the participant’s
health care needs—who is not involved in the research—
but an MRC may also be any qualified physician not
affiliated with the research study. While the primary role
of an MRC is to serve as an advisor to an individual or
LAR regarding research participation, additional duties
include: (1) confirming that a participant provided assent
to be enrolled in the research; (2) observing the individual
for possible dissent to continued participation; and (3)
monitoring the individual for any signs of harm as a
result of research participation.39 Thus, use of an MRC is
an important safeguard for high risk studies because the
physician acts as an advocate for cognitively impaired
individuals. The MRC serves as a mechanism to assure
that the physical and emotional well-being of participants
are looked after by an outside third party.
3.

Multiple Project Assurances (MPAs)

According to New York law, the consent of the
Commissioner of Health is required for all non-federally
regulated research involving “incompetent persons [and]
mentally disabled persons,” regardless of the risk category.40 However, to streamline the review process, the Task
Force recommends that the Department of Health should
develop MPAs41 to ensure a timely and thorough review
of research protocols by IRBs. An MPA is an assurance
between the Department of Health and a research entity
or institution that pledges that all members of the entity
or institution will comply with human subjects research
policies issued by the state.
The Task Force recommends the use of a state MPA
to obviate the need for full case-by-case Commissioner/
Department of Health review for research involving cognitively impaired individuals that involves minimal risk
or a minor increase over minimal risk, with or without a
prospect of direct benefit, and for research that involves
more than a minor increase over minimal risk with a
prospect of direct benefit. However, for research that
involves more than a minor increase over minimal risk,
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without a prospect of direct benefit, a state MPA should
not be a valid release from review by the Department
of Health. In these cases, if an IRB concludes that the
research is of vital importance to either current research
participants and/or those similarly situated, that the risks
are reasonable in relation to such vital importance, and
appropriate safeguards are in place, the Department of
Health may: (1) reject the study and the research could
not be approved by the IRB, (2) approve the study and
the research could be approved by the IRB, or (3) convene
a special review panel of experts which will review the
study and issue recommendations to the IRB on whether
the study should be approved, and the IRB will make the
final decision to approve or reject the protocol.

The disclosure of adverse events45 and unanticipated
problems46 that result from research participation promotes transparency and may further protect the welfare
of research participants.47 The Office of Human Research
Protections (OHRP) has suggested definitions of “adverse
events”—which are not (in all cases) necessarily reportable to the IRB or federal agency—and “unanticipated
problems” which must be reported; the definitions overlap but an occurrence might be either an adverse event or
an unanticipated problem without being the other. While
most adverse events are not unanticipated problems, and
only some unanticipated problems are adverse events,
only a small proportion of adverse events are unanticipated problems.

4.

Because the severity of any given adverse event
may range from minimal to serious, because the natural
progression of an illness or condition under study will
vary, and because the severity and frequency of anticipated problems inherent to the research will vary, IRBs
should determine, based on the research protocol, which
events would require immediate action by the researcher
or institution. Any reasonable possibility that a protocol
may have caused serious or life-threatening harm or
death requires immediate reporting and attention by the
researcher and IRB to provide any corrective or preventative action.

Reporting Requirements

While most research conducted in the state is federally regulated or overseen, there is a small portion of
research that is not under federal purview. The Task Force
recommends that research involving individuals unable
to provide consent under Public Health Law 24-A should
be subject to federal reporting requirements.42 These
reporting requirements will promote accountability and
transparency and may include, if appropriate, evaluations of capacity of participants, including the method(s)
used to assess capacity; procedures used to identify
LARs for surrogate consent to research; and a summary
of various risk levels involved in approved protocols.
Furthermore, the Task Force recommends that IRBs be
required to report to the Department any violations of approved principles and policies which the institution has
promulgated.43
The Task Force recommends that researchers conducting studies under New York State’s law governing
HSR that involve individuals unable to provide consent should be subject to federally mandated reporting
requirements and provide such documentation to the
IRB. Under federal regulations, researchers are required
to submit extensive documentation to an IRB as part of
the review and approval process.44 In addition, the Task
Force recommends that researchers should disclose relevant information to potential participants and LARs of
how the study will be ethically conducted to ensure that
the rights and welfare of participants are protected.
Once the study is under way, the Task Force recommends that researchers should provide regular updates
on the status of the participant and the general progress
of the study to the participant and/or LAR. They should
report any substantial concerns regarding an individual’s
participation to the LAR in ordinary language so that
s/he remains fully informed. In addition, the researcher
should remind participants and LARs of the availability of the researcher throughout the study to address
any questions. Only with full disclosure to participants,
LARs, and IRBs of the status and progress of the research
can all parties be confident that the study is being conducted in an ethical and safe manner.
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The Task Force recommends that for both IRBs and
researchers, any non-federal research protocol should
contain methods for the identification, management, and
reporting of adverse events and unanticipated problems
that may occur during the course of a research protocol,
comparable to those contemplated by the federal Common Rule.48

Conclusions
The Task Force’s Report and Recommendations for Research with Human Subjects Who Lack Consent Capacity are
the result of a multi-year effort to respond to appeals for
guidance from New York State IRBs, investigators, and
research institutions on how to conduct ethical research
involving adults who lack consent capacity. Although
New York State law governs human subjects research for
a subset of research conducted in the state by providing
mechanisms for ensuring voluntary informed consent for
participants and IRB review of research protocols, it does
not provide any special oversight mechanisms for research involving this particular population. Despite calls
to do so, federal law also does not provide safeguards
or special protections for research involving “mentally
disabled persons.”49 The absence of such guidelines or
regulations may lead to unethical or unsafe research protocols or the dearth of important research into the broad
range of diseases that impair cognition.
Thus, an underlying goal of the Task Force’s work
is to ensure that research protocols are available to all
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individuals, including individuals who lack consent
capacity, so that they may also experience the benefits,
risks, and burdens of research as their non-cognitively
impaired peers, while also ensuring the appropriate level
of protections. Although the guidelines focus only on the
inclusion of these individuals in research in New York
State, the recommendations could serve as a model for
the development of other policies in other states and at
the federal level.
For more information regarding the Task Force’s
analysis and recommendations, as well as more on the legal implications of research involving adults lacking consent capacity, see the Task Force’s full report, Report and
Recommendations for Research with Human Subjects Who
Lack Consent Capacity, at: http://www.health.ny.gov/
regulations/task_force/reports_publications/.
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